TEST:

DEEPGEN™ Panel

‍The DEEPGEN panel is unique in that the assay design provides both industry leading technical sensitivity and specificity in a large pan-cancer detection custom designed panel. The assay is comprised of a target panel of 272 genes identified to be related to cancer - through a proprietary machine learning algorithm. DEEPGEN ensures industry leading analytical and clinical performance. A combination of both proprietary and consensus markers, the panel contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines, lung cancer and colorectal cancer (CRC), and emerging cancer biomarkers. DEEPGEN achieves a true limit of detection of 1/1000 genome copies, better than any other available technology to date.